Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which co… Read more
Surrozen Inc (SRZN) - Net Assets
Latest net assets as of September 2025: $-23.52 Million USD
Based on the latest financial reports, Surrozen Inc (SRZN) has net assets worth $-23.52 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($94.05 Million) and total liabilities ($117.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-23.52 Million |
| % of Total Assets | -25.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | -145.21% |
| 10-Year Change | N/A |
| Growth Volatility | 98.63 |
Surrozen Inc - Net Assets Trend (2019–2024)
This chart illustrates how Surrozen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Surrozen Inc (2019–2024)
The table below shows the annual net assets of Surrozen Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-21.38 Million | -156.36% |
| 2023-12-31 | $37.94 Million | -50.09% |
| 2022-12-31 | $76.00 Million | -30.72% |
| 2021-12-31 | $109.70 Million | +131.96% |
| 2020-12-31 | $47.29 Million | +60.94% |
| 2019-12-31 | $29.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Surrozen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22997400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $263.88 Million | % |
| Total Equity | $-21.38 Million | 100.00% |
Surrozen Inc Competitors by Market Cap
The table below lists competitors of Surrozen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
$55.15 Million |
|
Bonraybio Co., Ltd.
TW:6955
|
$55.16 Million |
|
SKY Metals Ltd
AU:SKY
|
$55.16 Million |
|
Dicot AB
ST:DICOT
|
$55.17 Million |
|
Me2on Co. Ltd
KQ:201490
|
$55.14 Million |
|
KPX Chemical
KO:025000
|
$55.13 Million |
|
Jiangsu Recbio Technology Co., Ltd.
F:G93
|
$55.13 Million |
|
ZENTEK LTD.
F:ZAY0
|
$55.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Surrozen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 37,935,000 to -21,380,000, a change of -59,315,000 (-156.4%).
- Net loss of 63,564,000 reduced equity.
- Share repurchases of 94,000 reduced equity.
- New share issuances of 16,043,000 increased equity.
- Other factors decreased equity by 11,700,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-63.56 Million | -297.31% |
| Share Repurchases | $94.00K | -0.44% |
| Share Issuances | $16.04 Million | +75.04% |
| Other Changes | $-11.70 Million | -54.72% |
| Total Change | $- | -156.36% |
Book Value vs Market Value Analysis
This analysis compares Surrozen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $74.71 | $25.60 | x |
| 2020-12-31 | $59.44 | $25.60 | x |
| 2021-12-31 | $46.97 | $25.60 | x |
| 2022-12-31 | $32.83 | $25.60 | x |
| 2023-12-31 | $18.80 | $25.60 | x |
| 2024-12-31 | $-7.29 | $25.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Surrozen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -596.56%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-58.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -82.90% | 0.00% | 0.00x | 1.45x | $-27.30 Million |
| 2020 | -68.98% | 0.00% | 0.00x | 1.31x | $-37.35 Million |
| 2021 | -47.87% | 0.00% | 0.00x | 1.25x | $-63.48 Million |
| 2022 | -36.41% | -221.35% | 0.14x | 1.18x | $-35.27 Million |
| 2023 | -113.46% | -344.34% | 0.27x | 1.21x | $-46.84 Million |
| 2024 | 0.00% | -596.56% | 0.22x | 0.00x | $-61.43 Million |
Industry Comparison
This section compares Surrozen Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Surrozen Inc (SRZN) | $-23.52 Million | -82.90% | N/A | $55.14 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |